Baird analyst Joel Beatty initiated coverage of Pliant Therapeutics with an Outperform rating and $44 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PLRX:
- Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
- 3 Best Stocks to Buy Now, 3/28/2023, According to Top Analysts
- Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
- Pliant Therapeutics price target raised to $54 from $53 at H.C. Wainwright
- Pliant Therapeutics price target lowered to $50 from $55 at Citi